The results reveal that both the PDGC21T and the anti-CD49c antibody could bind to MDA-MB-231 xenograft-tumor cells (Figure S5B) but not MCF7 xenograft-tumor cells (Figure S5C), suggesting that the PDGC21T aptamer can target those TNBC-xenograft tumor cells with high expression of CD49c. Here, ITGA3 is linked to neoplasm.